Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legislation Seeks Space For Supplements On Health Care Reform Slate

This article was originally published in The Tan Sheet

Executive Summary

Carving out a role for the dietary supplement industry in health care reform has taken on a double-edged approach. While supporting legislation focused on establishing spending on supplements as health care expenses, the industry also backs including wellness and prevention programs in health care reform plans

You may also be interested in...



Harkin, Hatch Reload In Hunt For Full DSHEA Funding, Implementation

The supplement industry's staunchest allies in the Senate, Tom Harkin and Orrin Hatch, introduce a bill aimed at fully funding dietary supplement regulation and timed to deflect criticism of the industry from a committee hearing

Harkin, Hatch Reload In Hunt For Full DSHEA Funding, Implementation

The supplement industry's staunchest allies in the Senate, Tom Harkin and Orrin Hatch, introduce a bill aimed at fully funding dietary supplement regulation and timed to deflect criticism of the industry from a committee hearing

Harkin, Hatch Reload In Hunt For Full DSHEA Funding, Implementation

The supplement industry's staunchest allies in the Senate, Tom Harkin and Orrin Hatch, introduce a bill aimed at fully funding dietary supplement regulation and timed to deflect criticism of the industry from a committee hearing

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel